Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -72.55% is 162% below its 5-year average of 116.25%, near the low end of its 5-year range (-184.26%–646.39%).
As of the fiscal period ended Tuesday, March 31, 2026. 1284.49% below its 12-month average of 6.13%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2026-03-31.
RETURN ON EQUITY (ROE)
-72.55%
RETURN ON EQUITY (ROE) AVG TTM
6.13%
RETURN ON EQUITY (ROE) AVG 3Y
236.20%
RETURN ON EQUITY (ROE) AVG 5Y
116.25%
RETURN ON EQUITY (ROE) AVG 10Y
29.88%
RETURN ON EQUITY (ROE) AVG 15Y
-12.72%
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-1284.49%
CURRENT VS 3Y AVG
-130.72%
CURRENT VS 5Y AVG
-162.41%
CURRENT VS 10Y AVG
-342.79%
CURRENT VS 15Y AVG
-470.52%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.78%
median of 742 covered companies
CURRENT VS SECTOR MEDIAN
-73.63%
vs the sector median at left
OKYO Pharma Limited
Market Cap
$56.98M
Return on Equity (ROE)
-72.55%
TTM Avg
6.13%
3Y Avg
236.20%
5Y Avg
116.25%
Market Cap
$57.09M
Return on Equity (ROE)
-104.65%
TTM Avg
-123.21%
3Y Avg
-45.49%
5Y Avg
-1.96%
Market Cap
$57.69M
Return on Equity (ROE)
N/A
TTM Avg
71.44%
3Y Avg
1810.59%
5Y Avg
1190.90%
Market Cap
$58.16M
Return on Equity (ROE)
N/A
TTM Avg
-285.38%
3Y Avg
-206.98%
5Y Avg
-151.57%
Market Cap
$58.66M
Return on Equity (ROE)
-58.99%
TTM Avg
-51.19%
3Y Avg
-1.82%
5Y Avg
11.74%
Market Cap
$59.36M
Return on Equity (ROE)
-82.38%
TTM Avg
-68.06%
3Y Avg
-60.95%
5Y Avg
-49.61%
Market Cap
$59.25M
Return on Equity (ROE)
-132.16%
TTM Avg
-74.56%
3Y Avg
-71.32%
5Y Avg
22.85%
Market Cap
$54.10M
Return on Equity (ROE)
N/A
TTM Avg
171.70%
3Y Avg
384.85%
5Y Avg
251.73%
Market Cap
$60.03M
Return on Equity (ROE)
-30.21%
TTM Avg
-215.14%
3Y Avg
-180.32%
5Y Avg
47.11%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OKYO Pharma Limited (OKYO) | $56.98M | -72.55% | 6.13% | 236.20% | 116.25% |
| Talphera, Inc. (TLPH)vs › | $57.09M | -104.65% | -123.21% | -45.49% | -1.96% |
| MiNK Therapeutics, Inc. (INKT)vs › | $57.69M | N/A | 71.44% | 1810.59% | 1190.90% |
| PDS Biotechnology Corporation (PDSB)vs › | $58.16M | N/A | -285.38% | -206.98% | -151.57% |
| Boundless Bio, Inc. (BOLD)vs › | $58.66M | -58.99% | -51.19% | -1.82% | 11.74% |
| Adicet Bio, Inc. (ACET)vs › | $59.36M | -82.38% | -68.06% | -60.95% | -49.61% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.25M | -132.16% | -74.56% | -71.32% | 22.85% |
| Spectral AI, Inc. (MDAI)vs › | $54.10M | N/A | 171.70% | 384.85% | 251.73% |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.03M | -30.21% | -215.14% | -180.32% | 47.11% |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.21M | N/A | 85.37% | 6.44% | -23.00% |
ROE
-72.5%
ROA
-42.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -72.55% |
| 2025-03-31 | 84.80% |
| 2024-03-31 | 286.17% |
| 2023-03-31 | 646.39% |
| 2022-03-31 | -184.26% |
| 2021-03-31 | -63.05% |
| 2020-03-31 | 1103.12% |
| 2019-03-31 | -1469.36% |
| 2018-03-31 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-03-31 | -2.56% |
| 2015-03-31 | -24.35% |
| 2014-03-31 | -29.70% |
| 2013-03-31 | -10.75% |
| 2012-03-31 | -11.62% |
| 2011-03-31 | -10.10% |
| 2010-03-31 | 23.45% |
| 2009-03-31 | 37.54% |
| 2008-03-31 | -10.83% |
